Nuzenio

Fda Approves Replimune

Fda Approves Replimune news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 24 latest news signals 21 publisher sources 100/100 entity strength

Latest news

FDA Approves Replimune's Tudriqev for Advanced Melanoma After Two Previous Rejections - Medical DailyMedical Daily · Sat, 08 Aug 2026 14:30:41 GMTReplimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line - TradingViewTradingView · Sat, 08 Aug 2026 00:31:00 GMTRecovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA - medcitynews.commedcitynews.com · Fri, 07 Aug 2026 22:12:34 GMTAmid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - The Cancer LetterThe Cancer Letter · Fri, 07 Aug 2026 20:50:43 GMTReplimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. - Barron'sBarron's · Fri, 07 Aug 2026 19:33:00 GMTFDA Approves RP1 Plus Nivolumab for Advanced Melanoma - Dermatology TimesDermatology Times · Fri, 07 Aug 2026 19:11:16 GMTThird Time's the Charm: FDA Approves Replimune's Tudriqev (RP1) for Advanced Melanoma - OncodailyOncodaily · Fri, 07 Aug 2026 18:18:14 GMTFDA Grants Accelerated Approval to Replimune's Tudriqev Plus Nivolumab for Advanced Melanoma - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 17:19:39 GMT

Timeline

Sat, 08 Aug 2026 14:30:41 GMTFDA Approves Replimune's Tudriqev for Advanced Melanoma After Two Previous Rejections - Medical Daily
Sat, 08 Aug 2026 00:31:00 GMTReplimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line - TradingView
Fri, 07 Aug 2026 22:12:34 GMTRecovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA - medcitynews.com
Fri, 07 Aug 2026 20:50:43 GMTAmid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - The Cancer Letter
Fri, 07 Aug 2026 19:33:00 GMTReplimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. - Barron's
Fri, 07 Aug 2026 19:11:16 GMTFDA Approves RP1 Plus Nivolumab for Advanced Melanoma - Dermatology Times

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Fda Approves Replimune.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

21 distinct publisher/source names are currently connected to this entity page.